Phillip Grovenstein, a doctoral student in the Translational Biomedical Sciences program at Georgia State University’s Institute for Biomedical Sciences, has been awarded a two-year predoctoral fellowship grant totaling $89,658 from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The funding will support research aimed at developing a universal influenza vaccine.
Grovenstein’s work focuses on understanding how certain combinations of vaccines can boost immune responses and provide broader protection against various strains of flu. “Current seasonal flu vaccines offer limited and inconsistent protection due to frequent mutations in the virus,” Grovenstein said. “There’s a critical need for a more effective, broadly protective (universal) flu vaccine, especially as existing strategies targeting conserved viral regions have fallen short.
“My preliminary findings showed that mRNA-based vaccines targeting conserved viral elements like the M2e ectodomain and HA stem domain can provide cross-protection against multiple flu strains. Preliminary data revealed that a tandem repeat of M2e (5xM2e) mRNA vaccine can enhance immune responses when co-administered with other conventional flu vaccines. With the help of this grant, my proposed study aims to identify mechanisms of this vaccine combination to develop a broadly protective and more effective flu vaccination strategy.”
The NIH provides several fellowships supporting career development for young scientists. This particular award is affiliated with the Ruth L. Kirschstein National Research Service Award Predoctoral Fellowship (F31), which is designed to give promising predoctoral students individualized training under faculty mentors while they conduct dissertation research relevant to health-related scientific fields.
The fellowship includes tuition assistance, a stipend, and funds for books, equipment, and travel related to meetings or conferences. Applicants were required to submit comprehensive documentation about their academic background, details about their proposed project, letters of recommendation, and information about both university resources and mentor qualifications.
Sang-Moo Kang, Distinguished University Professor at Georgia State’s Institute for Biomedical Sciences, is serving as Grovenstein’s mentor during his research.
Grovenstein is currently in his fourth year as a Ph.D. student. He plans to pursue an independent research career in vaccine development within the biotech or biopharmaceutical industry after completing his degree.
